English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Aim: Examine clinical profile of extended-release topiramate (Trokendi XR ® ) and compare treatment-emergent adverse events (TEAEs) associated with Trokendi XR versus previous immediate-release topiramate (TPM-IR) treatment. Patients &amp; methods: Pilot retrospective study analyzing data extracted from medical charts of patients ≥6 years of age prescribed Trokendi XR. Results: Trokendi XR was the most commonly used to prevent migraine. The most common TEAEs recorded during topiramate treatment were cognitive symptoms (word-finding difficulty, attention/concentration difficulty, slowed thinking), paresthesia, gastrointestinal problems and decreased appetite/weight loss. TEAE incidence was significantly (p &lt; 0.001) lower during Trokendi XR versus previous TPM-IR treatment. Conclusion: Trokendi XR use and outcomes in clinical practice were consistent with established profile of topiramate. Results supported the potential for better tolerability of Trokendi XR versus TPM-IR.

journal of comparative effectiveness research

Real-world assessment of treatment with extended-release topiramate (Trokendi XR <sup>®</sup> ) and comparison with previous immediate-release topiramate treatment

Real-world assessment of treatment with extended-release topiramate (Trokendi XR ® ) and comparison with previous immediate-release topiramate treatment

Real-world assessment of treatment with extended-release topiramate (Trokendi XR ^® ) and comparison with previous immediate-release topiramate treatment